Literature DB >> 11014540

Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker.

K Harada1, K Kurisu, H Tahara, E Tahara, T Ide, E Tahara.   

Abstract

OBJECT: Telomerase activity is responsible for cell immortality. To examine the role of telomerase in the carcinogenesis of human glioblastomas multiforme (GBMs), the authors studied telomerase activity, telomerase component expression, and telomere lengths in 42 GBM samples.
METHODS: In all samples, EGFR and MDM2 amplifications and overexpressions were examined using Southern and Northern blot analyses. The p53 mutation was analyzed using polymerase chain reaction-single strand conformational polymorphism and by direct sequence analysis. Specimens of tissues were immunostained with p53, EGFR, and MDM2 antibodies. Allelic loss on chromosomes 17p and 10 was assessed by loss of heterozygosity (LOH) assays. Telomerase activity, expression of its components (human telomerase reverse transcriptase [hTERT], human telomerase RNA component [hTERC], and telomerase-associated protein [TEP1]), and telomere lengths were analyzed using the telomeric repeat amplification protocol (TRAP)-hybridization protection assay, reverse transcription-polymerase chain reaction, and Southern blot analysis. According to the results of assessments of EGFR and MDM2 amplifications, p53 mutation, LOHs in chromosomes 17p and 10, and the clinical course of the disease, the 42 samples were classified into 22 primary and 20 secondary glioblastomas. Twenty-six (61.9%) of all 42 samples demonstrated detectable telomerase activity during the TRAP assay. Secondary GBMs displayed significantly higher levels of telomerase activity and hTERT expression than primary GBMs. Tumors with a p53 gene mutation demonstrated significantly higher telomerase activity than those without a p53 mutation. Four samples with a codon 175 mutation demonstrated an exceptionally high amount of telomerase activity. In secondary GBMs, the increase in telomerase activity and the hTERT expression level correlated with the increased frequency of p53 mutations. There was no significant difference in telomere length between primary and secondary GBMs.
CONCLUSIONS: These results suggest that telomerase activity and p53 mutations both play important roles in the multistep carcinogenesis of GBMs. Telomerase activity and hTERT expression may be considered as novel distinctive factors in human GBMs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014540     DOI: 10.3171/jns.2000.93.4.0618

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

1.  Progression of astrocytomas and meningiomas: an evaluation in vitro.

Authors:  L Maes; J P O Kalala; M Cornelissen; L de Ridder
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.

Authors:  Matthias Simon; Ismail Hosen; Konstantinos Gousias; Sivaramakrishna Rachakonda; Barbara Heidenreich; Marco Gessi; Johannes Schramm; Kari Hemminki; Andreas Waha; Rajiv Kumar
Journal:  Neuro Oncol       Date:  2014-08-18       Impact factor: 12.300

3.  Experimental Curative Fluorescence-guided Surgery of Highly Invasive Glioblastoma Multiforme Selectively Labeled With a Killer-reporter Adenovirus.

Authors:  Shuya Yano; Shinji Miwa; Hiroyuki Kishimoto; Makoto Toneri; Yukihiko Hiroshima; Mako Yamamoto; Michael Bouvet; Yasuo Urata; Hiroshi Tazawa; Shunsuke Kagawa; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

Review 4.  Cancer stem cells: the final frontier for glioma virotherapy.

Authors:  Mahua Dey; Ilya V Ulasov; Matthew A Tyler; Adam M Sonabend; Maciej S Lesniak
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

5.  MMP-9 silencing regulates hTERT expression via β1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells.

Authors:  Shivani Ponnala; Chandramu Chetty; Krishna Kumar Veeravalli; Dzung H Dinh; Jeffrey D Klopfenstein; Jasti S Rao
Journal:  Cell Signal       Date:  2011-08-09       Impact factor: 4.315

Review 6.  Glioma: what is the role of c-Myc, hsp90 and telomerase?

Authors:  A Shervington; N Cruickshanks; H Wright; R Atkinson-Dell; R Lea; G Roberts; L Shervington
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

7.  TERT expression increases with tumor grade in a cohort of IDH-mutant gliomas.

Authors:  Anvesh Jalasutram; John L Caniglia; Kiran K Velpula; Maheedhara R Guda; Sarah E Bach; Andrew J Tsung
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

8.  The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.

Authors:  Calin O Marian; Steve K Cho; Brian M McEllin; Elizabeth A Maher; Kimmo J Hatanpaa; Christopher J Madden; Bruce E Mickey; Woodring E Wright; Jerry W Shay; Robert M Bachoo
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

9.  Suramin increased telomerase activity in the c6 glioma/wistar experimental brain tumor model.

Authors:  Mine Ergüven; Ayhan Bilir; Tuncay Altug; Fadime Aktar; Nuriye Akev
Journal:  Int J Biomed Sci       Date:  2007-06

10.  mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.

Authors:  A Yannopoulos; E Dimitriadis; A Scorilas; T Trangas; E Markakis; M Talieri
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.